Skip to main content

CG Oncology, Inc 8-K, filed Nov 16, 2026

CG Oncology, Inc. (CGON)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

CG Oncology, Inc filed this 8-K on November 16, 2026.

CG Oncology reported that PIVOT-006 met its primary endpoint, with cretostimogene reducing recurrence risk by 68% (hazard ratio 0.32; 95% CI: 0.23, 0.45; p<0.0001). BLAs are planned for March 2027 and the second quarter of 2027. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits